




Fourth Quarter and Full Year 2023

Earnings Highlights

Full Year Highlights



Fourth Quarter Highlights



"In 2023, Pfizer received a record number of nine New Molecular Entity approvals by the U.S. Food and Drug Administration (FDA) — medicines and vaccines that are expected to favorably impact Pfizer's performance in the coming years. We are entering 2024 with a solid foundation. We believe our commitment to execution, maximizing the performance of our new products, and delivering the next wave of pipeline innovation will fuel Pfizer's growth and make a difference in the lives of patients everywhere."


Albert Bourla
Chairman and Chief Executive Officer



2023 Full-Year Global Pharmaceuticals Revenues



Key Revenue Growth Drivers



Pipeline Spotlights⁵



~618M Patients Treated
Worldwide in 2023 with our medicines and vaccines⁶

Fortifying Long-Term Growth Plans




What's Next

Remains confident in ability to deliver operational growth and meaningful shareholder value long term.



ANTICIPATES

Non-COVID-19 2024 operational revenue growth of 8% to 10% inclusive of Seagen⁸



investors.pfizer.com

Please reference Pfizer's Q4 and Full Year 2023 earnings release and SEC filings for additional information.

¹ Operational growth. Reference to operational variances pertains to period-over-period changes that exclude the impact of foreign exchange rates.
² Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for Q4 and Full Year 2023 and 2022 accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated January 30, 2024. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income/(loss) and its components and diluted EPS/(LPS). See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2022 Annual Report on Form 10-K and the Non-GAAP Financial Measure: Adjusted Income section accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated January 30, 2024, for additional information.

³ Total company guidance. Please see Pfizer's press release issued on December 13, 2023, as well as Pfizer's Q4 and Full Year 2023 earnings release for additional details and assumptions regarding Pfizer's 2024 financial guidance.

⁴ Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan.

⁵ Pipeline updates as of January 30, 2024.

⁶ The Patients Treated metric is calculated from Pfizer and third-party datasets. This estimate does not include Seagen patients treated. Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage) and are subject to change. Numbers are estimates and, in some cases, use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologies to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple patients towards total. Numbers do not include comprehensive estimated patient counts from Ex-U.S. Access & Affordability programs. Historical estimates may periodically be subject to revision due to restatements in the underlying data source.

⁷ Reference the full set of materials in the Q4 and Full Year 2023 Earnings Presentation for certain information regarding potential product launches. Through H1 2024, we expect to have up to 18 new products or indications in the market – including the 16 for which we have already begun co-promotion or commercialization in 2022 and through 2023. All dates are preliminary, subject to change and subject to, among other risks, assumptions and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.